Trinity Biotech plc American Depositary Shares (TRIB)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable advantages, honest earnings, and a margin of safety. Trinity Biotech sells diagnostic tests and instruments to clinical labs and point-of-care users. That is a necessary field, but the numbers are poor. In the latest filed quarter, fiscal Q4 2024, revenue was $15.9 million and net income was -$17.0 million, a negative 106.93% margin. Costs and charges exceeded sales by a wide margin. The company employed 287 people, so it is very small and shows no scale advantage I can identify. The FairStock Score is 20/100, the Piotroski F-Score is 2/9, and the Altman Z-Score is -2.82; those are FairStock calculations from the supplied data. Return on capital employed is -5.72%, so capital is being consumed, not compounded. At the 2026-10-13 close of $6.30, market capitalization was $12.8 million and the FairStock P/E was -0.11, meaningless because earnings are negative. Book value and debt-to-equity are not available, but the negative Z-score suggests distress risk. The 52-week range of $0.31 to $14.17 shows wild speculation. There is no dividend, revenue and profit growth are not available, and the Lynch category is none because only zero years of filed results are available, while three are needed. Without a moat, consistent profits, or a clear margin of safety, this is not a Graham-style bargain. It is a speculative turnaround at best.

In plain English: Trinity Biotech makes medical tests for laboratories and clinics. The business looks weak: it lost money in its latest reported quarter and the numbers point to serious money trouble. At $6.30 a share, the price looks risky and is not clearly supported by profits.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer